Shares of Dutch immunology specialist Argenx (Euronext: ARGX) have dropped around a tenth following negative results from the ADVANCE-SC study.
The company is trialing Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), which was recently approved for generalized myasthenia gravis, as an option for adults with primary immune thrombocytopenia (ITP).
Top-line results now show the study missed its primary efficacy endpoint of a sustained platelet count response in chronic ITP patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze